OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
IMHM57

Intermedical Care and Lab Hospital PCL

Healthcare Facilities & ServicesVerified

Capital Structure and Liquidity Intermedical Care and Lab Hospital PCL exhibits a debt-to-equity ratio of 1.99, indicating a capital structure heavily reliant on debt financing. The company's liquidity position is characterized by a current ratio of 0.4, suggesting limited short-term liquidity. With only THB 28.64 million in cash and equivalents and THB 1.08 billion in long-term debt, the firm faces a net cash outflow after accounting for total debt obligations. ### Profitability and Returns The company's profitability is underperforming relative to industry norms, with a return on equity (ROE) of -34.76% and a return on assets (ROA) of -8.98%. These negative returns indicate that the company is not generating sufficient returns to cover its cost of capital or asset base, which is a concern for investors seeking capital appreciation. ### Segments and Geographic Exposure The company's revenue is distributed across three segments: Hospital, Occupational Medicine Hospital, and Environmental analysis. While the input data does not specify the exact revenue contribution of each segment, the company's services are offered nationwide through mobile X-ray trucks, indicating a broad geographic footprint. However, the lack of detailed segment revenue data limits the ability to assess concentration risk within specific business lines. ### Growth Trajectory The company reported a revenue of THB 754.92 million in the latest period, but its operating and net income are negative, at THB -126.15 million and THB -188.69 million, respectively. The absence of forward-looking revenue guidance or outlook data makes it difficult to assess the company's growth trajectory. The negative operating cash flow of THB -163.84 million further suggests that the company is not generating sufficient cash from operations to sustain or grow its business. ### Risk Factors The company faces medium liquidity risk due to its low current ratio and negative free cash flow. The risk assessment also flags a net cash outflow after subtracting total debt, which could constrain the company's ability to meet short-term obligations. While the dilution risk is currently assessed as low, the company's reliance on debt financing and negative cash flows could increase the likelihood of future dilution through equity issuance or debt restructuring. ### Recent Events No recent filings or transcripts are provided in the input data to inform on recent corporate developments or strategic initiatives. The absence of such information limits the ability to assess the company's response to market conditions or operational challenges.

30-day price · IMHM(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyIntermedical Care and Lab Hospital PCL
TickerIMHM.BK
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Intermedical Care and Lab Hospital PCL operates as a private hospital specializing in occupational medicine, providing health check-up services, vaccination services, and first aid training through its Hospital, Occupational Medicine Hospital, and Environmental analysis segments.

Classification. The company is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a confidence level of 0.92 based on verified market data.

### Capital Structure and Liquidity Intermedical Care and Lab Hospital PCL exhibits a debt-to-equity ratio of 1.99, indicating a capital structure heavily reliant on debt financing. The company's liquidity position is characterized by a current ratio of 0.4, suggesting limited short-term liquidity. With only THB 28.64 million in cash and equivalents and THB 1.08 billion in long-term debt, the firm faces a net cash outflow after accounting for total debt obligations. ### Profitability and Returns The company's profitability is underperforming relative to industry norms, with a return on equity (ROE) of -34.76% and a return on assets (ROA) of -8.98%. These negative returns indicate that the company is not generating sufficient returns to cover its cost of capital or asset base, which is a concern for investors seeking capital appreciation. ### Segments and Geographic Exposure The company's revenue is distributed across three segments: Hospital, Occupational Medicine Hospital, and Environmental analysis. While the input data does not specify the exact revenue contribution of each segment, the company's services are offered nationwide through mobile X-ray trucks, indicating a broad geographic footprint. However, the lack of detailed segment revenue data limits the ability to assess concentration risk within specific business lines. ### Growth Trajectory The company reported a revenue of THB 754.92 million in the latest period, but its operating and net income are negative, at THB -126.15 million and THB -188.69 million, respectively. The absence of forward-looking revenue guidance or outlook data makes it difficult to assess the company's growth trajectory. The negative operating cash flow of THB -163.84 million further suggests that the company is not generating sufficient cash from operations to sustain or grow its business. ### Risk Factors The company faces medium liquidity risk due to its low current ratio and negative free cash flow. The risk assessment also flags a net cash outflow after subtracting total debt, which could constrain the company's ability to meet short-term obligations. While the dilution risk is currently assessed as low, the company's reliance on debt financing and negative cash flows could increase the likelihood of future dilution through equity issuance or debt restructuring. ### Recent Events No recent filings or transcripts are provided in the input data to inform on recent corporate developments or strategic initiatives. The absence of such information limits the ability to assess the company's response to market conditions or operational challenges.
Key takeaways
  • The company's capital structure is heavily leveraged, with a debt-to-equity ratio of 1.99.
  • Negative returns on equity and assets indicate poor capital efficiency and asset utilization.
  • The company's liquidity position is weak, with a current ratio of 0.4 and negative free cash flow.
  • The absence of segment-specific revenue data limits the ability to assess business line performance.
  • The company's growth trajectory is uncertain due to negative operating and net income.
  • The risk of future dilution remains low, but liquidity constraints could pressure the company to issue equity.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyTHB
Revenue$754.9M
Gross profit$101.7M
Operating income-$126.2M
Net income-$188.7M
R&D
SG&A
D&A
SBC
Operating cash flow$146.9M
CapEx-$25.1M
Free cash flow-$163.8M
Total assets$2.10B
Total liabilities$1.56B
Total equity$542.8M
Cash & equivalents$28.6M
Long-term debt$1.08B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$542.8M
Net cash-$1.05B
Current ratio0.4
Debt/Equity2.0
ROA-9.0%
ROE-34.8%
Cash conversion-78.0%
CapEx/Revenue-3.3%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 25 companies
MetricIMHMActivity
Op margin-16.7%18.2% medp25 18.2% · p75 24.6%bottom quartile
Net margin-25.0%14.7% medp25 11.7% · p75 28.1%bottom quartile
Gross margin13.5%19.7% medp25 19.7% · p75 39.8%bottom quartile
R&D / revenue24.3% medp25 6.6% · p75 24.3%
CapEx / revenue-3.3%4.9% medp25 4.2% · p75 6.3%bottom quartile
Debt / equity199.0%71.3% medp25 19.0% · p75 91.7%top quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 12:54 UTC#219a9ac5
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 12:57 UTCJob: eed1cae6